GlassScriptPhysician profile
Victoria E Haydar
NPI 1538340237
$7,685.99
in general payments reported to CMS, 2019-2025
25 companies · $698 in 2025
The $698 reported for 2025 was more than what 79% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,565 · 2020: $625 · 2021: $1,053 · 2022: $726 · 2023: $1,053 · 2024: $966 · 2025: $698.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,717.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,717.06 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,654.79 | 2019-2025 | Ofev, Jardiance, Synjardy |
| Astrazeneca Pharmaceuticals LP | $1,590.77 | 2019-2024 | Farxiga |
| Glaxosmithkline, LLC. | $1,528.12 | 2019-2025 | Nucala, Trelegy Ellipta |
| Lilly USA, LLC | $959.95 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Actelion Pharmaceuticals US, INC. | $237.17 | 2019-2023 | Uptravi, Opsumit |
| Novo Nordisk INC | $226.17 | 2019-2025 | Ozempic, Rybelsus |
| Bausch Health US, LLC | $194.92 | 2019-2024 | Aplenzin |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $168.18 | 2020-2024 | Xifaxan |
| Heartflow, INC. | $147.18 | 2024 | |
| Merck Sharp & Dohme LLC | $136.50 | 2019-2020 | |
| Amgen INC. | $130.27 | 2019 | |
| Ibsa Pharma INC. | $121.88 | 2020-2022 | |
| Mallinckrodt Enterprises LLC | $108.35 | 2019 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $91.23 | 2025 | Caplyta |
| Allergan, INC. | $62.24 | 2019-2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $52.24 | 2020-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $52.18 | 2019-2021 | |
| Verona Pharma, INC. | $46.17 | 2025 | Ohtuvayre |
| Sunovion Pharmaceuticals INC. | $40.73 | 2019 | |
| Currax Pharmaceuticals LLC | $38.11 | 2019-2020 | |
| Insmed, INC. | $28.68 | 2025 | Brinsupri |
| United Therapeutics Corporation | $23.59 | 2023 | Tyvaso |
| Janssen Pharmaceuticals, INC | $17.75 | 2019 | |
| Pfizer INC. | $16.42 | 2024 | |
| Nalpropion Pharmaceuticals LLC | $12.40 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victoria Haydar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.